Introduction {#s1}
============

The acute respiratory distress syndrome (ARDS), a clinically important complication of severe acute lung injury (ALI) in humans, is a significant cause of morbidity and mortality in critically ill patients \[[@pmed-0040269-b001]--[@pmed-0040269-b004]\]. Infectious etiologies, such as sepsis and pneumonia, are leading causes of ALI/ARDS \[[@pmed-0040269-b001],[@pmed-0040269-b002]\]. Histologically, ALI/ARDS in humans is characterized by a severe acute inflammatory response in the lungs and neutrophilic alveolitis \[[@pmed-0040269-b001]\]. Inflammatory stimuli from microbial pathogens, such as endotoxin (lipopolysaccharide \[LPS\]), are well recognized for their ability to induce pulmonary inflammation, and experimental administration of LPS, both systemically and intratracheally, has been used to induce pulmonary inflammation in animal models of ALI \[[@pmed-0040269-b005]--[@pmed-0040269-b009]\].

The physiological hallmark of ARDS is disruption of the alveolar--capillary membrane barrier (i.e., pulmonary vascular leak), leading to development of noncardiogenic pulmonary edema, in which a proteinaceous exudate floods the alveolar spaces, impairs gas exchange, and precipitates respiratory failure \[[@pmed-0040269-b001],[@pmed-0040269-b010],[@pmed-0040269-b011]\]. Both alveolar epithelial and endothelial cell (EC) injury and/or death have been implicated in the pathogenesis of ALI/ARDS \[[@pmed-0040269-b001]\]. However, despite decades of research, few therapeutic strategies for clinical ARDS have emerged, and current specific options for treatment are limited \[[@pmed-0040269-b012]--[@pmed-0040269-b016]\]. ARDS continues to be an important contributor to prolonged mechanical ventilation in the intensive care unit, and ARDS-associated mortality remains high at 30%--50% despite optimal supportive care \[[@pmed-0040269-b001],[@pmed-0040269-b013],[@pmed-0040269-b014],[@pmed-0040269-b016]\].

Marrow-derived stem or progenitor cells are being evaluated for the treatment of a number of diseases that currently have limited or no treatment options \[[@pmed-0040269-b017]--[@pmed-0040269-b022]\]. Recent studies have demonstrated that bone marrow-derived mesenchymal stem cells (MSCs) \[[@pmed-0040269-b023],[@pmed-0040269-b024]\] can engraft in the injured lung \[[@pmed-0040269-b025],[@pmed-0040269-b026]\] and even differentiate into lung epithelial cells in vivo \[[@pmed-0040269-b025],[@pmed-0040269-b027],[@pmed-0040269-b028]\]. MSCs may also exhibit immunosuppressive properties and have been suggested to be "immune-privileged", and thus are protected from rejection, potentially permitting their use in allotransplantation \[[@pmed-0040269-b029]--[@pmed-0040269-b034]\]. Therefore, MSCs may have beneficial effects in their own right in the therapy of ALI \[[@pmed-0040269-b035]\].

Human angiopoeitin 1 (ANGPT1), a ligand for the endothelial-restricted receptor TEK tyrosine kinase (TEK; previously called TIE2) \[[@pmed-0040269-b036],[@pmed-0040269-b037]\], plays an essential role in blood vessel maturation and stabilization during embryonic development. In the postnatal state, ANGPT1 maintains the normal quiescent phenotype of vascular ECs, protecting against vascular inflammation \[[@pmed-0040269-b038],[@pmed-0040269-b039]\], reducing permeability \[[@pmed-0040269-b040]--[@pmed-0040269-b042]\], and promoting EC survival \[[@pmed-0040269-b043]--[@pmed-0040269-b046]\]. Given its anti-inflammatory, antipermeability, and endothelial-protective characteristics, we hypothesized that *ANGPT1* gene transfer may be beneficial in the treatment of ALI.

The combination of cell and gene therapies has proven successful in the treatment of experimental pulmonary hypertension \[[@pmed-0040269-b047]--[@pmed-0040269-b051]\]. This dual strategy not only allows direct targeting of the lung for clinical intervention, but also provides a site-specific source to release therapeutic proteins and/or other cellular products of interest by the retained cells. Therefore, the aim of this study was to evaluate the effect of MSCs alone or in combination with the vasculoprotective factor ANGPT1 on lung inflammation and injury induced by LPS in a murine model of ALI.

Materials and Methods {#s2}
=====================

Characterization, Culture, and Transfection of MSCs {#s2a}
---------------------------------------------------

A frozen vial of murine MSCs (isolated from male C57Bl/6J mice; courtesy of Tulane Center for Gene Therapy, New Orleans, Louisiana, United States) was thawed and expanded as previously described \[[@pmed-0040269-b052]\]. Differentiation of MSCs was evaluated using a Mesenchymal Stem Cell Functional Identification Kit (R&D Systems, <http://www.rndsystems.com/>). Chondrogenic and osteogenic differentiation assays were performed in six-well Primaria plates (BD Biosciences, <http://www.bdbiosciences.com/>). The adipogenic assay was performed in eight-well Lab-Tek II Chamber Slide System (NUNC, <http://www.nuncbrand.com/>). MSCs were labeled with anti-mouse antibodies Sca-1 (clone E13--161.7), CD31 (clone MEC13.3), CD34 (clone RAM34), VCAM-1 (clone 429\[MVCAM.A\]), Flk1 (clone Avas 12a1), cKit (clone 2B8), CD45R (clone RA3-6B2), and CD11b (clone M1/70) and corresponding isotype controls purchased from BD Biosciences, and analyzed by flow cytometer (Cytomics FC500, Beckman Coulter, <http://www.beckmancoulter.com/>). MSCs used in all in vivo experiments were between passages 8 and 11. The full-length coding sequence of *ANGPT1* (1115 bp) was cloned into the expression vector pFLAG-CMV-1 (Sigma, <http://www.sigmaaldrich.com/>) as previously described \[[@pmed-0040269-b051]\]. MSCs were transfected by nuclear-targeting electroporation (nucleofection, Amaxa, <http://www.amaxa.com/>), SuperFect (activated dendrimer, Qiagen, <http://www.qiagen.com/>) or Lipofectamine (cationic lipids, Invitrogen, <http://www.invitrogen.com/>). For the in vivo study, nuclear-targeting electroporation was used to transfect MSCs with *ANGPT1* plasmid or empty vector plasmid. Human ANGPT1 protein expression was verified by ELISA (R&D Systems).

Murine Model of LPS-Induced ALI {#s2b}
-------------------------------

All animal procedures were approved in advance by the Animal Care Committee of St. Michael\'s Hospital (Toronto, Ontario, Canada). Carboxy-fluorescein diacetate, succinimidyl ester (Vybrant CFDA SE Cell Tracer Kit, Invitrogen) was used to label cells before injection into the animals. Aliquots of MSCs were analyzed by flow cytometry to confirm complete labeling. Female mice (19.9 ± 1.3 g) were anaesthetized and orally intubated with a sterile plastic catheter, and challenged with intratracheal instillation of 800 μg of LPS (E. coli 055:B5; Sigma) dissolved in 50 μl of normal saline. Saline, MSCs, MSCs transfected with pFLAG (MSCs-pFLAG), or MSCs transfected by plasmid containing human *ANGPT1* (MSCs-pANGPT1) (2.5 × 10^5^ cells, 100 μl total volume) were slowly infused via a jugular venous canula 30 min following LPS challenge. Human ANGPT1 protein expression was confirmed by ELISA for each batch of MSCs-pANGPT1 employed. Naïve mice (without LPS instillation) were injected with saline or MSCs to serve as controls for any inflammatory response that might result from the injected MSCs. After infusion, the canula was withdrawn, the vein ligated, and the incision sutured using silk suture. Mice were humanely killed at 15 min or 3 d after MSC treatment to collect tissues for analysis.

Due to the small size of the animals, two measurement groups were required to collect all tissue samples required. In one set of animals (*n* = 5 per group), lungs were lavaged three times with 1 ml of saline. Total cell counts were determined using a haemocytometer. Differential cell counts were determined on BAL smear slides that were stained with Hemacolor (EMD Chemicals, <http://www.emdbiosciences.com/>). Number of neutrophils was calculated as the percentage of neutrophils multiplied by the total number of cells in the BAL fluid sample. BAL fluid collected was then centrifuged at 800 *g*, and supernatant was collected for analysis of total protein, albumin, IgM, and cytokine/chemokine levels. All analyses were performed in a blinded fashion. The abdominal aorta and vena cava were severed at the diaphragm, and the right ventricle of the heart perfused with 10 ml of heparinized saline. The left lower lobe of the lung was snap-frozen, and later processed for lung homogenates. The rest of the lung was digested with dispase II (3.6 U/ml; Roche, <http://www.roche.com/>) into a single-cell suspension, according to a previously published protocol \[[@pmed-0040269-b053]\]. In another set of animals (*n* = 5 per group, except for the LPS/saline group \[*n* = 9\] and the LPS/MSCs group \[*n* = 10\]), blood was collected with a heparinized needle through cardiac puncture, and later centrifuged at 2,000 *g* to obtain plasma sample. Lungs were divided into two parts: the left lower lobe was collected as frozen tissue in OCT (Optimal Cutting Temperature; SAKURA FINETEK, <http://www.sakura-americas.com/>) and the rest was fixed by 4% paraformaldehyde for histology.

Histopathology {#s2c}
--------------

Lung tissues (two cross sections of right lower lobe and one of right upper lobe) were fixed in 4% paraformaldehyde, embedded in paraffin, and cut into 5-μm thick sections. Sections were stained with hematoxylin and eosin, and images were taken with a Nikon Eclipse E800 microscope with a 40× objective. The average interalveolar septal thickness was quantified in a blinded fashion by measuring the thickness of all septae along a crosshair placed on each image (at least 150 septa per animal), using ImageJ software (National Institutes of Health; <http://rsb.info.nih.gov/>). For the lung injury score, images were evaluated by a investigator who was blinded to the identity of the slides (WCL) following a previously published scoring system \[[@pmed-0040269-b054]\].

Measurement of Albumin, IgM, Cytokines, and Chemokines {#s2d}
------------------------------------------------------

Albumin and IgM levels in BAL fluid samples were measured using with a murine-specific albumin ELISA kit (ALPCO Diagnostics, <http://www.alpco.com/>) and a murine-specific IgM ELISA kit (Bethyl Laboratories, <http://www.bethyl.com/>), respectively. Cytokine levels (IFN-γ, TNF-α, IL6, and IL1β) in BAL fluid were measured with murine cytokine-specific Quantikine ELISA kits (R&D Systems). Chemokine levels in BAL fluid, and cytokine/chemokine levels in lung homogenates and plasma, were measured by multiplex immunoassay (Luminex 100, Luminex, <http://www.luminexcorp.com/>) using cytokine-specific bead kits (R&D Systems). Lung homogenates were processed according to a previously published protocol \[[@pmed-0040269-b055]\], and all results were normalized (25 μg of total protein per sample) with individual protein concentration measured from lung homogenate samples by Bradford assay (Bio-Rad, <http://www.bio-rad.com/>).

MSCs Rentention Study {#s2e}
---------------------

Mouse lung was digested into single cells using dispase II enzyme (3.6 U/ml, Roche) according to a previously published protocol \[[@pmed-0040269-b053]\]. The number of total cells recovered was determined by using a hemocytometer. Isolated cells were analyzed by a flow cytometer (FC500, Beckman Coulter) with a minimal collection of 30,000 events per sample. Cell nuclei were counterstained with nuclear dye TO-PRO-3 (Invitrogen), and confocal microscopic images were collected with a Leica TCS SL laser scanning confocal microscope.

Statistics {#s2f}
----------

Data in figures are represented as individual data points in a vertical dot plot, with a line to indicate the mean, except data for surface marker expression on MSCs, and retention of injected MSCs, in which data are represented as bar graphs showing mean ± standard error of the mean (SEM). Lung injury score and septal thickness data are shown in tabular form (mean ± SEM). Differences between the treated groups versus the injured group (LPS/saline) were assessed using a one-way ANOVA (with post hoc comparisons using Dunnett test) with statistic software (GraphPad Prism version 4.00; <http://www.graphpad.com/>). A value of *p* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Characterization and *ANGPT1* Transfection of MSCs {#s3a}
--------------------------------------------------

Murine MSCs were demonstrated to differentiate into three predominant mesenchymal lineages: adipocytes, osteocytes, and chondrocytes ([Figure 1](#pmed-0040269-g001){ref-type="fig"}A--[1](#pmed-0040269-g001){ref-type="fig"}D). The cells were uniformly positive for the stem cell surface marker Sca1 by flow cytometry ([Figure 1](#pmed-0040269-g001){ref-type="fig"}E). Subpopulations of MSCs were CD34^+^ and VCAM1^+^, as previously reported for murine MSCs from the C57Bl/6J background \[[@pmed-0040269-b052]\]. The cells were negative for both CD11b (monocyte marker) and CD45R (leukocyte marker).

![Characterization of MSCs Isolated from C57Bl/6J Mice, and Experimental Design for In Vivo Study\
(A) Undifferentiated MSCs (P8) were seeded in a T75 flask at a density of 100 cells/cm^2^ and found to expand readily in a fashion that started from a single cell to colony.\
(B) Staining with oil red-O was used to detect MSCs that differentiated into adipocytes, identified by perinuclear red staining of fat globules.\
(C) Staining with alizarian red was used to detect MSCs that differentiated into osteocytes.\
(D) MSCs that differentiated into chondrocytes were stained with toluidine blue. Photomicrographs were obtained with a 10× (A and C) or a 20× (B and D) objective using a Nikon Eclipse TS100 inverted microscope.\
(E) Flow cytometry was performed for surface marker expression on cultured MSCs. All data are presented as mean ± SEM.\
(F) C57Bl/6J mice initially received LPS by intratracheal instillation, followed by intravenous injection 30 min later with saline, cultured MSCs, MSCs-pFLAG, or MSCs-pANGPT1. Mice were then sacrificed 15 min and 3 d after to assess cell retention, or 3 d after to evaluate the therapeutic efficacy. A photomicrograph of MSCs-pANGPT1 was obtained using a Nikon Eclipse TS100 inverted microscope with a 10× objective 1 d after transfection and prior to injection into animals.](pmed.0040269.g001){#pmed-0040269-g001}

Flow cytometric analysis of MSCs transfected by nuclear-targeting electroporation resulted in ∼55% greater GFP expression in live cells compared to transfection with either SuperFect or Lipofectamine (unpublished data). At 24 h after nucleofection with pANGPT1, ANGPT1 protein (724 ± 283 pg/ml) was detected in the culture supernatant (from 5 × 10^5^ cells), and levels were sustained for more than 5 d ([Figure S1](#pmed-0040269-sg001){ref-type="supplementary-material"}; detailed methods described in [Protocol S1](#pmed-0040269-sd001){ref-type="supplementary-material"}). Phosphorylation of the TEK receptor, mediated by human ANGPT1 protein expressed using the same plasmid, has been previously validated by our group \[[@pmed-0040269-b051]\]. Nontransfected or null-transfected (empty vector) MSCs produced no detectable ANGPT1 protein.

Effect of MSCs Alone or Transfected with *ANGPT1* on Acute LPS-Induced Pulmonary Inflammation {#s3b}
---------------------------------------------------------------------------------------------

LPS was administered to mice followed by an injection of saline, MSCs alone, or MSCs transfected with pFLAG (null) or *ANGPT1* plasmid (MSCs-pANGPT1) ([Figure 1](#pmed-0040269-g001){ref-type="fig"}F). The total inflammatory cell count in the BAL fluid was increased approximately 20-fold at day 3 following administration of LPS, mainly attributable to an increase in neutrophils (around 80% of total cells in LPS/saline group). Treatment of animals with MSCs alone significantly reduced the total cell and neutrophil counts in BAL fluid ([Figure 2](#pmed-0040269-g002){ref-type="fig"}A and [2](#pmed-0040269-g002){ref-type="fig"}B, *p* \< 0.05 compared to LPS/saline group). Treatment with MSCs-pANGPT1 further reduced the BAL fluid cell count to a level similar to control, naïve mice (*p* \< 0.01 for total cells and neutrophils counts compared to LPS/saline group). Substitution of skin fibroblasts or unfractionated bone marrow cells for MSCs did not prevent the observed LPS-induced increase in BAL fluid cell counts (unpublished data).

![Therapeutic Potential of MSCs, Alone or Transfected with pANGPT1*,* on LPS-Induced Lung Inflammation in Mice\
(A and B) Total cell (A) and neutrophil (B) counts were performed on BAL fluid to evaluate lung airspace inflammation. There was a 19-fold increase in total inflammatory cells in BAL fluid collected 3 d after LPS, which was reduced by 53% in MSCs-treated mice (non-/null-transfected), and by 96% with MSCs-pANGPT1. Group comparisons were analyzed by one-way ANOVA with Dunnett post hoc test. \**p* \< 0.05 and \*\**p* \< 0.01, compared between LPS/saline versus each treated group (MSCs, MSCs-pFLAG, or MSCs-pANGPT1). *n* = 5 per group.\
(C) Histological evaluation of therapeutic potential of MSCs and MSCs-pANGPT1 on LPS-induced lung injury in mice. Representative images of hematoxylin and eosin stained lung sections from six experimental groups. Lungs were fixed with 4% paraformaldehyde, embedded in paraffin, and then cut into 5-μm thick sections before being stained. Photomicrographs were obtained with a Nikon Eclipse E800 microscope with a 40× objective. Scale bar = 20 μm.](pmed.0040269.g002){#pmed-0040269-g002}

Histological assessment of lung sections 3 d after the administration of LPS revealed evidence of marked inflammatory infiltrates, interalveolar septal thickening, and interstitial edema ([Figure 2](#pmed-0040269-g002){ref-type="fig"}C). MSCs alone reduced airspace inflammation, which was more apparent in mice treated with MSCs-pANGPT1. Morphometric analysis measuring interalveolar septal thickness showed a modest increase in the LPS alone group, with a significant reduction in animals receiving MSCs ([Table 1](#pmed-0040269-t001){ref-type="table"}). Severity of lung injury was also scored using a semiquantitative histopathology score system \[[@pmed-0040269-b054]\], which evaluates lung injury in four categories: alveolar septae, alveolar hemorrhage, intra-alveolar fibrin, and intra-alveolar infiltrates. Although treatment with MSCs or MSCs-pANGPT1 tended to reduce lung injury scores ([Table 1](#pmed-0040269-t001){ref-type="table"}), the observed differences did not reach statistical significance.

###### 

Lung Injury Score and Septal Thickness in Mice with LPS-Induced ALI

![](pmed.0040269.t001)

To further evaluate the anti-inflammatory actions by MSCs and MSCs-pANGPT1, levels of proinflammatory cytokines and chemokines were measured in BAL fluid collected from animals. Proinflammatory cytokines (IFN-γ, TNF-α, IL6, and IL1β) were all elevated in BAL fluid in response to LPS challenge compared with naïve animals receiving saline ([Figure 3](#pmed-0040269-g003){ref-type="fig"}). Treatment with MSCs alone variably decreased the levels of proinflammatory cytokines, while treatment with MSCs-pANGPT1 dramatically reduced cytokine levels to the baseline values observed in naïve mice. LPS instillation also increased the levels of Cxcl2, JE (the murine homolog of human CCL2), and KC (the murine homolog of human IL8) in BAL fluid, whereas treatment with MSCs, and to a greater extent MSCs-pANGPT1, attenuated these increases. Similarly, LPS-induced cytokine and chemokine levels in whole lung homogenates were significantly reduced by treatment with MSCs or MSCs-pANGPT1 ([Figure 4](#pmed-0040269-g004){ref-type="fig"}), however, in this case MSCs alone did not differ significantly from MSCs-pANGPT1 in reducing proinflammatory cytokine and chemokine levels. Discrepancies in BAL cytokine levels between animals that received non- or null-transfected MSCs were occasionally noted, likely reflecting biological variability, since mice receiving null-transfected MSCs usually showed results similar to those in mice that received nontransfected MSCs. No detectable differences in cytokine and chemokine levels in plasma were observed among different treatment groups 3 d after treatment, suggesting that intratracheal LPS instillation induced localized inflammation in the lungs, and did not result in prolonged systemic inflammation in our model (unpublished data).

![Levels of Proinflammatory Cytokines and Chemokines in BAL Fluid\
Levels of the proinflammatory cytokines IFN-γ, TNF-α, IL6, and IL1β in BAL fluid were measured using ELISA. In addition, chemokine levels (Cxcl2, JE \[murine homolog of human CCL2\], and KC \[murine IL8 homolog\]) in BAL fluid were measured by multiplex immunoassay. Group comparisons were analyzed by one-way ANOVA with Dunnett post hoc test. \**p* \< 0.05 and \*\**p* \< 0.01, LPS/saline versus each treated group (MSCs, MSCs-pFLAG, or MSCs-pANGPT1). *n* = 5 per group.](pmed.0040269.g003){#pmed-0040269-g003}

![Levels of Proinflammatory Cytokines and Chemokines in Lung Homogenate\
Cytokine (TNF-α and IL6) and chemokine (Cxcl2, JE \[murine homolog of human CCL2\], and KC \[murine IL8 homolog\]) levels in lung homogenates were measured by multiplex immunoassay. Group comparisons were analyzed by one-way ANOVA with Dunnett post hoc test. \**p* \< 0.05 and \*\**p* \< 0.01, LPS/saline versus each treated group (MSCs, MSCs-pFLAG, or MSCs-pANGPT1). *n* = 5 per group.](pmed.0040269.g004){#pmed-0040269-g004}

Effect of MSCs and MSCs-pANGPT1 on LPS-Induced Lung Permeability {#s3c}
----------------------------------------------------------------

Concentrations of total protein, albumin, and IgM were assayed on collected BAL fluid to evaluate the integrity of the alveolar--capillary membrane barrier and assess pulmonary vascular leakage as a marker for ALI. These parameters of vascular leak were markedly increased (total protein, 3-fold; albumin, 4-fold; and IgM, 25-fold) in BAL fluid 3 d after LPS instillation compared to naïve mice. Whereas treatment with MSCs alone partially reduced total protein, albumin, and IgM levels ([Figure 5](#pmed-0040269-g005){ref-type="fig"}), treatment with MSCs-pANGPT1 restored these lung injury indicators to levels not different from naïve control mice (*p* \< 0.01 for total proteins and albumin, and *p* \< 0.05 for IgM compared to LPS/saline group, respectively). To assess apoptosis in LPS-induced ALI mice with or without treatment, caspase 3 and 7 activities were measured in lung homogenate samples. Activities of caspase 3 and 7 in mouse lungs tended to be increased 3 d after animals received intratracheal instillation of LPS, which was normalized only in mice that received MSCs-pANGPT1 treatment ([Figure S2](#pmed-0040269-sg002){ref-type="supplementary-material"}; detailed method described in [Protocol S1](#pmed-0040269-sd001){ref-type="supplementary-material"}).

![Effect of MSCs and MSCs-pANGPT1 on LPS-Induced ALI\
Therapeutic efficacy was assessed by measurement of total protein, albumin, and IgM (biomarkers of pulmonary vascular leakage resulting from disruption of the alveolar--capillary membrane barrier) in BAL fluid. (A) Total protein concentration was measured by Bradford assay (A); albumin was measured using a mouse-specific albumin ELISA (B); and IgM was measured using a mouse IgM ELISA kit (C). Group comparisons were analyzed by one-way ANOVA with Dunnett post hoc test. \**p* \< 0.05 and \*\**p* \< 0.01, LPS/saline versus each treated group (MSCs, MSCs-pFLAG, or MSCs-pANGPT1). *n* = 5 per group.](pmed.0040269.g005){#pmed-0040269-g005}

Persistence of MSCs in Mice with or without LPS-Induced ALI {#s3d}
-----------------------------------------------------------

Retention of MSCs in the lung after central venous injection was verified by confocal microscopy and flow cytometry. MSCs labeled with the green fluorescent cell tracker CFDA SE \[[@pmed-0040269-b056]\] were observed in lung sections from both naïve and LPS-challenged mice sacrificed at 15 min (initial retention, [Figure 6](#pmed-0040269-g006){ref-type="fig"}A). Although labeled cells could still be detected 3 d after injection, they were far less abundant ([Figure 6](#pmed-0040269-g006){ref-type="fig"}C). No cell-specific green fluorescence was observed in sections from animals that did not receive CFDA SE-labeled cells (unpublished figure). To confirm that the green fluorescence observed was indeed from an intact cell, a z-series using laser scanning confocal microscopy was performed showing blue nuclear staining surrounded by green fluorescence by CFDA SE labeling ([Figure 6](#pmed-0040269-g006){ref-type="fig"}B). The percentage of the injected MSCs retained in the lungs was quantified by flow cytometry following dispase lung digestion. An average 47% of injected cells were found in the lungs shortly after MSCs delivery in LPS-challenged mouse lungs comparing to 38% in naïve mice, though the difference was not statistically significant. Regardless of lung injury, the majority of MSCs were lost from the lung after 3 d, leaving less than 8% of cells remaining ([Figure 6](#pmed-0040269-g006){ref-type="fig"}D).

![Retention of Injected MSCs in Mice With or Without LPS-Induced ALI\
MSCs were labeled with the cell tracing dye CFDA SE (green) prior to injection. Nuclei were stained with TO-PRO-3 (blue). Scale bars in photomicrographs = 20 μm. White arrows indicate labeled MSCs.\
(A) Labeled MSCs were observed in 5 μm, PFA-fixed lung sections from LPS-injured mice sacrificed at 15 min (initial retention). Image obtained with a Leica laser scanning confocal microscope with a 20× objective.\
(B) A three-dimensional lung section from an animal that received labeled MSCs. Lung was inflated, stored in OCT, and cut into 50 μm thick sections. Z-series images (30 sections, total thickness of the tissue scanned = 17.71 μm) were collected with a 63× oil objective and projected in different axes, as shown. Red autofluorescence shows outline of the alveolus.\
(C) pANGPT1-transfected MSCs labeled with the green fluorescent cell tracker CFDA SE were observed in lung section from LPS-injured mice killed at 3 d. Photomicrographs were taken in z-axis with a 20× objective, then images were stacked using Leica confocal software.\
(D) Lung lobes (left upper and all right lobes) from each animal were enzyme-digested into single cells before MSCs were counted by flow cytometry. *n* = 5 per group.](pmed.0040269.g006){#pmed-0040269-g006}

Discussion {#s4}
==========

In the present study, we demonstrate in a murine model of ALI that administration of MSCs to the pulmonary circulation partially prevented LPS-induced lung inflammation, whereas treatment with pANGPT1-transfected MSCs resulted in further improvement in both alveolar inflammation and permeability. These findings have potentially important implications for the treatment of ARDS, a clinical syndrome resulting from ALI, which represents an important therapeutic problem contributing to high morbidity and mortality of critically ill patients.

Cell-based gene transfer can overcome some of the limitations of direct gene therapy for pulmonary diseases \[[@pmed-0040269-b057]\], achieving selective and durable transgene expression in the lung \[[@pmed-0040269-b048]--[@pmed-0040269-b051],[@pmed-0040269-b058]\]. Since stem and progenitor cells have also been reported to restore function of damaged tissue in various preclinical disease models \[[@pmed-0040269-b047],[@pmed-0040269-b048]\], it follows that combining stem cell therapy with gene therapy might provide additive benefits. Indeed, we have reported that endothelial progenitor cells engineered to overexpress endothelial NO synthase were significantly more effective than endothelial progenitor cells alone in a monocrotaline model of vascular injury, producing near complete reversal of established pulmonary hypertension \[[@pmed-0040269-b048]\].

The choice of the most appropriate therapeutic gene is a critical determinant of the potential efficacy of a gene therapy strategy, and requires a detailed understanding of the pathogenic mechanisms underlying the target disorder. ARDS is a complex clinical syndrome that is initiated by injury to the lung, often in the setting of pneumonia or sepsis. Some of the early features of ARDS can be reproduced by administration of bacterial endotoxin (LPS), which acts via TLR4 (Toll-like receptor 4) to induce the expression of inflammatory cytokines and chemokines and up-regulate leukocyte adhesion molecules, resulting in EC activation \[[@pmed-0040269-b005]--[@pmed-0040269-b009],[@pmed-0040269-b059]\]. Recently, it has been observed that activation of ECs in response to inflammatory cytokines is tightly regulated by ANGPT1. ANGPT1, the principal agonist of TEK, is an EC survival and vascular stabilization factor that maintains endothelial permeability in the normal postnatal vasculature \[[@pmed-0040269-b039]--[@pmed-0040269-b042]\]. In contrast, ANGPT2, which binds with equal affinity, has been described as a TEK antagonist, inhibiting receptor activation in response to ANGPT1 \[[@pmed-0040269-b060]\]. Fiedler et al. showed that ANGPT2 overexpression sensitized ECs to inflammatory stimuli and potentiated the up-regulation of adhesion molecules such as ICAM1 and VCAM1 in response to suboptimal doses of TNF-α \[[@pmed-0040269-b061]\]. Circulating levels of ANGPT2 were found to be elevated in the plasma of patients suffering from sepsis, and the administration of ANGPT2 led to disruption of endothelial barrier both in vitro and in a mouse model in vivo \[[@pmed-0040269-b062]\]. Moreover, ANGPT2 expression was recently observed to be increased in alveolar epithelial cells in response to hyperoxia-induced ALI, whereas ANGPT1 expression was reduced \[[@pmed-0040269-b063]\].

Therefore, a therapeutic strategy to restore the balance between ANGPT1 and ANGPT2 expression may be useful in modulating endothelial activation and inflammation in response to ALI. Systemic pretreatment with an adenoviral construct containing *ANGPT1* by Witzenbichler et al. was reported to improve hemodynamics, reduce adhesion molecule expression and prolong survival in mice with endotoxic shock \[[@pmed-0040269-b064]\]. Similarly, we have shown that fibroblasts transfected with *ANGPT1* were moderately effective in reducing ALI in rats when given one day prior to LPS, attenuating airspace inflammation by 60% and reducing expression of endothelial-selective adhesion molecules \[[@pmed-0040269-b065]\]. However, in these studies gene transfer was performed prior to lung injury, and it is uncertain whether post-treatment strategies, which are more relevant for clinical therapy, would have been equally effective. Furthermore, the Witzenbichler study used intraperitoneal administration of endotoxin and systemic gene therapy \[[@pmed-0040269-b064]\], and it is not possible to differentiate local actions of ANGPT1 on lung inflammation from its actions in the peripheral circulation.

The observed therapeutic effect of MSCs alone in ALI was not entirely unexpected, since previous reports have suggested that MSCs can inhibit the activation of dendritic cells, T lymphocytes, and natural killer cells, reducing the secretion of inflammatory cytokines (i.e., TNF-α, IFN-γ), increasing the release of anti-inflammatory cytokines (i.e., IL10, IL4), and inducing a tolerant phenotype \[[@pmed-0040269-b066],[@pmed-0040269-b067]\]. The immunomodulatory effects of MSCs have been studied in a number of inflammatory states such as graft-versus-host disease \[[@pmed-0040269-b068]\] and autoimmune encephalomyelitis \[[@pmed-0040269-b069]\]. It has also been suggested that the immunosuppressive activity of MSCs, together with their lack of expression of class II major histocompatibility complex antigens, may confer an "immune-privileged" state in the context of allogenic transplantation, which could greatly simplify their therapeutic use. Indeed, in early clinical trials, the use of cultured allogenic MSCs was shown to be well tolerated, and did not induce a detectable immune response when transplanted into an unrelated recipient \[[@pmed-0040269-b030],[@pmed-0040269-b070]\].

In the present study, there was an additional effect of ANGPT1 overexpressing MSCs compared with MSCs alone, not only on the extravasation of plasma proteins and inflammatory cells, but also on the levels of various inflammatory cytokines and chemokines in the BAL fluid. Interestingly, this additive effect was not apparent when these mediators were measured in whole-lung homogenates. ANGPT1 acts on TEK receptors, which are largely restricted to the endothelium. Thus, it is likely that ANGPT1 would have a preferential effect on the vascular endothelium, reducing inflammatory cell trafficking and plasma protein exudation into the alveolar space, and possibly inhibiting EC apoptosis as well. In contrast, effects of LPS on the airway epithelium or resident alveolar macrophages may not be directly modulated by ANGPT1. However, it should be noted that MSCs alone resulted in a near complete reduction of tissue cytokine expression, with the exception of Cxcl2, which in fact was further reduced in the group receiving with pANGPT1-transfected MSCs. It is also of interest that near complete normalization of protein and inflammatory cell exudation into the alveolus after intratracheal LPS instillation was achieved with MSCs-pANGPT1 delivered to the pulmonary circulation, despite the fact that alveolar permeability is determined by the functional integrity of both the alveolar epithelium and the alveolar endothelium, which together constitute the alveolar--capillary membrane barrier of the lung \[[@pmed-0040269-b001]\]. It has been well documented that LPS-induced ALI is associated with up-regulation of adhesion molecules on the endothelial surface \[[@pmed-0040269-b071]\]. Leukocyte adhesion to the activated endothelium is a critical determinant of the alveolar inflammatory response, leading to transmigration of inflammatory cells into the airspace and possible exacerbation of epithelial injury and increased pulmonary vascular leak \[[@pmed-0040269-b071]\]. Thus, the synergistic effect of *ANGPT1* gene transfer may be attributed to its ability to reduce EC activation and thus block the amplification of lung injury that is dependent on the recruitment of leukocytes from the pulmonary circulation into the injured lung.

On a separate note, we were unable to detect a significant increase in human ANGPT1 proteins in the lung tissue, BAL fluid, or plasma (unpublished data) after injection of pANGPT1-transfected MSCs. We believe that this is due to the lack of specific antibodies to human ANGPT1 that can reliably detect the human *ANGPT1* transgene product above the "noise" of the endogenous mouse proteins. In a separate study in which mice were allowed to survive up to 2 wk, a 20% mortality (up to 9 d) was observed in the LPS/saline group. No animals died in either the LPS/MSCs group or the LPS/MSCs-pANGPT1 group (unpublished data). We have also examined the effect of MSCs and MSCs-pANGPT1 at earlier time points (unpublished data). There was no difference in the total cell counts in BAL fluid in LPS-injured mice that received treatment with either MSCs or MSCs-pANGPT1, compared to the LPS/saline group (1 d after LPS injury). However, 2 d after LPS injury and treatment, there was a significant decrease in the total cell count in BAL fluid from mice that received MSCs and MSCs-pANGPT1 compared to controls, though the difference between those two groups was not significant. Preliminary data measuring the systemic level of IL1β suggested that plasma IL1β level peaked in LPS-injured mice (1 d after LPS) without treatment (LPS/saline mice), while most mice that had received treatment (LPS/MSCs or LPS/MSCs-pANGPT1) had lower or undetectable levels. Plasma IL1β rapidly declined in LPS-injured mice 2 d after injury. Mice that had received treatment (MSCs or MSCs-pANGPT1) had lower or undetectable levels.

We also examined whether the observed therapeutic effects depended on the retention of MSCs. A slightly higher proportion of cells were retained in injured lungs 15 minutes after LPS exposure; however, the difference between injured versus uninjured lung was not significant, and in both cases the majority of cells were lost from the lung by 3 d. Our results are in agreement with those of Beckett et al., who reported no significant improvement in lung engraftment of bone marrow-derived cells following endotoxin- or NO~2~-induced lung injury together with irradiation \[[@pmed-0040269-b072]\]. However, other studies have reported greater cell persistence after certain forms of injury \[[@pmed-0040269-b026],[@pmed-0040269-b073]--[@pmed-0040269-b075]\]. Nonetheless, it is clear that the benefit seen in response to cell-based therapy in the LPS injury model did not require a high level of long-term persistence of transplanted MSCs. This observation is consistent with a number of reports of bone marrow cell therapy following myocardial infarction \[[@pmed-0040269-b076],[@pmed-0040269-b077]\], which point to an important role for paracrine actions of transplanted cells on neovascularization and tissue healing. However, the precise mechanism by which genetically engineered MSCs confer a therapeutic benefit in the model of ALI remains to be determined.

Study Limitations {#s4a}
-----------------

It is important to recognize certain limitations of this study. First of all, the LPS-induced model of ALI cannot fully reproduce the complexity of clinical ALI/ARDS in human patients. Therefore, it will be necessary to reproduce these findings in more clinically relevant models, such as in animal models of sepsis and pneumonia. As well, cell therapy was given only 30 min after lung injury, and it will be important to define the therapeutic window of this intervention at later time points. Moreover, percentages of the retained cells in the lung after transplantation were fairly low, and future studies need to address the question of whether higher levels of MSCs incorporation would provide more therapeutic benefit in this and other models of ALI. A further limitation relates to the use syngeneic cells for cell therapy in the current study, which avoids the issue of host immune response. However, given the growing literature that these MSCs may be "immune-privileged," it will be important in future work to explore whether the use of allogenic MSCs will have the same beneficial effects in this ALI model. The translation of these promising results into an effective new therapy for ARDS in patients will require, at the very least, that these limitations be addressed.

Conclusion {#s4b}
----------

In conclusion, we have shown that bone marrow-derived MSCs reduced the severity of ALI when administered into the pulmonary circulation of the LPS-injured mouse lung, possibly by virtue of their well-characterized immunomodulatory actions. However, this effect was greatly potentiated when these cells were engineered to overexpress the vasculoprotective factor ANGPT1, a specific inhibitor of inflammation and permeability in ECs. Our data show, to our knowledge for the first time, the synergistic action of combined cell and gene therapy for ALI, and may provide a basis for the development of an innovative approach for the prevention and treatment of ARDS, which continues to be a major cause of morbidity and mortality in critically ill patients.

Supporting Information {#s5}
======================

###### Establishment of Optimal Conditions for Transfection of Murine MSCs

MSCs were transfected by nuclear-targeting electroporation with pFLAG (null transfection control using high efficiency protocol, solid bar) or pANGPT1 (high cell survival or high efficiency protocol; grey or diagonal stripes bar, respectively). Supernatants were collected for 7 d and ANGPT1 proteins produced by nucleofected cells each day was quantified using ELISA. All plotted values represent net ANGPT1 proteins produced, in which the amount of ANGPT1 determined from a medium alone control was subtracted (239.74 pg/ml). All data are presented as mean ± SEM.

(219 KB TIF)

###### 

Click here for additional data file.

###### Caspase 3 and 7 Activity in Lung Homogenate

Caspase 3 and Caspase 7 activities in mouse lung homogenates were measured by a commercially available kit. *n* = 5 per group.

(70 KB TIF)

###### 

Click here for additional data file.

###### Detailed Information on Transfection of Murine MSCs and Measurement of Caspase-3/7 Activities in Lung Samples

(20 KB DOC)

###### 

Click here for additional data file.

Accession Numbers {#s5a}
-----------------

The GenBank (<http://www.ncbi.nlm.nih.gov/>) accession numbers of the genes discussed in this paper are *ANGPT1* (GeneID 284); *ANGPT2* (GeneID 285); *TEK* (GeneID 7010).
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ALI

:   acute lung injury

ANGPT1

:   human angiopoietin 1

ANGPT2

:   human angiopoietin 2

ARDS

:   acute respiratory distress syndrome

BAL

:   bronchoalveolar lavage

CFDA SE

:   carboxyfluorescein diacetate, succinimidyl ester

EC

:   endothelial cell

LPS

:   lipopolysaccharide

MSC

:   mesenchymal stem cell

MSCs-pANGPT1

:   MSCs transfected with plasmid containing human *ANGPT1* gene

pANGPT1

:   plasmid containing human *ANGPT1* gene

SEM

:   standard error of the mean

TEK

:   TEK tyrosine kinase
